HOME BIOSCIENCES

Home Biosciences: A new breed of biotech

Q3 2022

Home Biosciences' co-founders

David Schilansky: strong track record of building & financing companies

- International profile (FR, US, UK)
- Dual track (M&A and industry)
  - *Investment banker at Warburg*
  - *CFO of Ipsen*
  - *d-CEO of DBV*
- Multiple mid-size BD and M&A transactions
- Scaled-up DBVT, raised more than $1 billion (NASDAQ & Euronext)

Magali Richard: scientist with strong track record in strategy & business model designs

- Scientific education (X, PhD in Bio)
- Dual track (R&D and business)
  - *Scientist at Biomarin*
  - *Principal at BCG*
  - *Chief Strategy Officer of DBV*
- US and EU biotech execution and strategy design
- Engineered multiple new business models for Life Sciences companies

HBS: a differentiated value-proposition in the EU biopharma landscape

HBS aims to become **a fully-fledged biotech company**

Building a long-term pipeline out of European science
in under-invested unmet medical needs

Increasing probabilities of success
by de-risking thoroughly incubated early-stage programs

Reducing execution bottlenecks by creating ‘execution SPVs’ and leveraging an asset-centric operating model

HBS aims to assemble **a total of five programs in the coming years**
First up & running SPV: One Biosciences

HBS operates along an asset-centric model

Leveraging HBS' team & structure across multiple programs

Partnering with academia and ensuring the **optimal positioning of scientific founders for project success**

Housing each program in dedicated SPVs, **fully funding them to enable focus of execution teams on day-to-day operations**

Creating cost-efficient structures benefiting from an efficient capital allocation

HBS' model is attractive and allows to build a strong ecosystem of talents, ensuring agility for execution



Home Biosciences is backed by strong shareholders

Investor board members

Redmile Group — *Ming Fang*

Sofinnova partners — *Antoine Papiernik*

1 $15 m seed equity investment

HOME BIOSCIENCES

2 HBS: a biotech company that incubates, builds, funds and operates SPVs

PROJECTS HOUSED IN DEDICATED VENTURES

HBS focuses initially on highly debilitating musculoskeletal and metabolic diseases

HBS investigates all incoming projects
that have life-changing potential in unmet medical needs

Initial priorities	Kidney & bone metabolism
	Muscular disorders
	Pain management

HBS remains opportunistic and investigates
therapeutic areas, treatment modalities and technology platforms,
where there is poor, or no therapeutic option

HBS is building its pipeline along different therapeutic areas, treatment modalities and technology platforms

Drug candidates

IP-generating platforms

Potential first-in-classes with increased PoS and strong biomarkers or validated targets in well-defined populations

HBS' first program takes advantage from the emerging revolution in the field of -omics biology

ONE BIOSCIENCES

One Biosciences combines AI & single-cell technologies…

- SPV co-founded with Institut Curie and Dr. Vallot, a leading team and platform in the field
- One Biosciences has created competitive edge, notably by building a unique suite of computational & AI tools and by being able to generate high quality data from frozen samples

… to discover new targets and develop first in class therapeutics

- Discovery engine designed to identify new targets and first-in-class drug candidates in oncology & beyond
- Model designed to partner with academics, clinicians, disease experts and potentially pharmacos
- Four projects ongoing in oncology and beyond

One Biosciences aims to unlock a new wave of therapeutic targets for difficult-to-treat diseases

- One Biosciences (OBS) has built a powerful, fully integrated discovery engine that combines AI & Single Cell technologies to discover new targets and develop first in class therapeutics
- OBS has less than a handful of peers worldwide and is unique in Europe
- On this extremely small set of peers, all tackling a huge field, **OBS has positioned itself with an original approach and key differentiating elements**:
  - Ability to work on **frozen biopsies** and generate high-quality data
  - **Versatility of the discovery engine** to identify cell vulnerabilities in both tumor and its microenvironment
  - **Fast, collaborative & interactive data analysis** of large complex datasets by AI algorithms

The combination of a largely untapped field and key differentiating assets make OBS' playing field and ambitions unique in AI & Single-Cell assisted drug discovery in oncology

One Biosciences' pipeline of projects